

Figure S1. Expression of PPAR γ by RT-qPCR in simvastatin- (SIM) or PBS-treated (CON) cells at day 3, 7 and 14 post differentiation (n=3) during adipogenic differentiation. Fold change was expressed as relative to the CON group, and the data are expressed as the means \pm SD. Data were analyzed by a Student's t-test; *P<0.05. BMSCs, bone marrow-derived mesenchymal stem cells; PPAR γ , peroxisome proliferator-activated receptor γ .




Figure S2. Role of GPR1 during adipogenesis in BMSCs. (A) Expression levels of GPR1 after simvastatin (SIM) or PBS (CON) treatment at days 3, 7 and 14 post-differentiation were analyzed by RT-qPCR (n=3). Data were analyzed by the Student's t-test; **P<0.01. (B) BMSCs were transfected with or without adenovirus 48 h before differentiation. At days 3 and 14 post-differentiation, cells that exhibited adipogenic differentiation with PBS (CON) or simvastatin (SIM) treatment were analyzed by RT-qPCR for GPR1 expression (n=3). Data were examined by analysis of variance followed by the LSD post hoc test; *P<0.05, **P<0.01 and ***P<0.001. (C) At days 3 and 14 post-differentiation, cells that exhibited adipogenic differentiation with PBS (CON), rosiglitazone (ROSI), rosiglitazone and simvastatin (ROSI + SIM) or simvastatin (SIM) treatment were analyzed by RT-qPCR for GPR1 expression (n=3). Fold change was expressed relative to the CON group, and the data are expressed as the means \pm SD. Data were examined by analysis of variance followed by the LSD post hoc test; *P<0.05 and **P<0.01. BLANK, untransfected cells; NC, negative control; CKD, CMKLR1 knockdown; BMSCs, bone marrow-derived mesenchymal stem cells; GPR, G protein-coupled receptor.




Figure S3. Immunofluorescence staining of each group of BMSCs after 48 h of transfection with adenovirus (magnification, x100). BLANK, untransfected cells; NC, negative control; CKD, CMKLR1 knockdown; BMSCs, bone marrow-derived mesenchymal stem cells.




Figure S4. Western blot analysis of CMKLR1 and the loading control β -actin in each group of BMSCs after 48 h of transfection with adenovirus. (A) The density of the protein bands was quantified and calculated using Gelpro32 4.0 software. (B) Data were examined by analysis of variance followed by the LSD post hoc test; *** $P < 0.001$. BLANK, untransfected cells; NC, negative control; CKD, CMKLR1 knockdown; BMSCs, bone marrow-derived mesenchymal stem cells; CMKLR1, chemokine-like receptor 1.




Table SI. Analysis by ANOVA followed by Dunnett's post hoc test of the data for CCK-8 assay presented in Fig. 1.

Variable	(I) group	(J) group	Average difference (I-J)	Standard error	Significance (P-value)	95% Confidence interval	
						Lower limit	Upper limit
Day 1	10 ⁻⁵	CON	-.05800 ^a	.01423	.002	-.0957	-.0203
	10 ⁻⁶	CON	-.01400	.01423	.725	-.0517	.0237
	10 ⁻⁷	CON	-.01000	.01423	.889	-.0477	.0277
	10 ⁻⁸	CON	-.00600	.01423	.980	-.0437	.0317
Day 2	10 ⁻⁵	CON	-.25600 ^a	.01400	<.001	-.2931	-.2189
	10 ⁻⁶	CON	-.17000 ^a	.01400	<.001	-.2071	-.1329
	10 ⁻⁷	CON	-.00200	.01400	1.000	-.0391	.0351
	10 ⁻⁸	CON	.03400	.01400	.078	-.0031	.0711
Day 3	10 ⁻⁵	CON	-.74800 ^a	.01552	<.001	-.7891	-.7069
	10 ⁻⁶	CON	-.51400 ^a	.01552	<.001	-.5551	-.4729
	10 ⁻⁷	CON	-.02400	.01552	.367	-.0651	.0171
	10 ⁻⁸	CON	-.04800 ^a	.01552	.020	-.0891	-.0069
Day 4	10 ⁻⁵	CON	-.88000 ^a	.01217	<.001	-.9123	-.8477
	10 ⁻⁶	CON	-.56000 ^a	.01217	<.001	-.5923	-.5277
	10 ⁻⁷	CON	-.07000 ^a	.01217	<.001	-.1023	-.0377
	10 ⁻⁸	CON	.09400 ^a	.01217	<.001	.0617	.1263
Day 5	10 ⁻⁵	CON	-1.01800 ^a	.01531	<.001	-1.0586	-.9774
	10 ⁻⁶	CON	-.67400 ^a	.01531	<.001	-.7146	-.6334
	10 ⁻⁷	CON	-.04600 ^a	.01531	.024	-.0866	-.0054
	10 ⁻⁸	CON	.08200 ^a	.01531	<.001	.0414	.1226

ANOVA, analysis of variance; CCK-8, Cell Counting kit-8. ^aThe average difference was significant at the 0.05 level.

Table SII. Analysis by ANOVA followed by the LSD post hoc test of the data for Oil Red O staining presented in Fig. 1.

(I) Group	(J) Group	Average difference (I-J)	Standard error	Significance (P-value)	95% Confidence interval	
					Lower limit	Upper limit
SIM	A	-.21000 ^a	.09022	.048	-.4180	-.0020
	B	-.09667	.09022	.315	-.3047	.1114
	CON	-.43000 ^a	.09022	.001	-.6380	-.2220
A	SIM	.21000 ^a	.09022	.048	.0020	.4180
	B	.11333	.09022	.244	-.0947	.3214
	CON	-.22000 ^a	.09022	.041	-.4280	-.0120
B	SIM	.09667	.09022	.315	-.1114	.3047
	A	-.11333	.09022	.244	-.3214	.0947
	CON	-.33333 ^a	.09022	.006	-.5414	-.1253
CON	SIM	.43000 ^a	.09022	.001	.2220	.6380
	A	.22000 ^a	.09022	.041	.0120	.4280
	B	.33333 ^a	.09022	.006	.1253	.5414

ANOVA, analysis of variance; SIM, BMSCs treated with simvastatin for 14 days; A, for the first 3 days; B, after 3 days; CON, with PBS for 14 days. ^aThe average difference was significant at the 0.05 level.

Table SIII. Analysis by Student's t-test of the data of the paired samples of the 3-day group presented in Figs. 2, S1 and S2A.

	Difference						
		Average	Standard deviation	Average standard error	95% Confidence interval		Significance (two-tailed P-value)
					Lower limit	Upper limit	
Pair group 1	PPAR γ CON - PPAR γ SIM	.14000	.04583	.02646	.02616	.25384	.034
Pair group 2	Adiponectin CON - adiponectin SIM	.06000	.19287	.11136	-.41912	.53912	.644
Pair group 3	Chemerin CON - chemerin SIM	.02000	.29513	.17039	-.71314	.75314	.917
Pair group 4	CMKLR1 CON - CMKLR1 SIM	.12333	.12220	.07055	-.18023	.42690	.223
Pair group 5	GPR1 CON - GPR1 SIM	-.05000	.13892	.08021	-.39511	.29511	.597

PPAR γ , peroxisome proliferator-activated receptor γ ; CMKLR1, chemokine-like receptor 1; GPR1, G protein-coupled receptor 1; CON, control; SIM, simvastatin.

Table SIV. Analysis by Student's t-test of the data of the paired samples of the 7-day group presented in Figs. 2, S1 and S2A.

	Difference	95% Confidence interval					Significance (two-tailed P-value)
		Average	Standard deviation	Average standard error	Lower limit	Upper limit	
Pair group 1	PPAR γ CON - PPAR γ SIM	.22333	.08963	.05175	.00068	.44598	.050
Pair group 2	Adiponectin CON - adiponectin SIM	.18333	.12097	.06984	-.11717	.48384	.120
Pair group 3	Chemerin CON - chemerin SIM	.17333	.08083	.04667	-.02746	.37412	.065
Pair group 4	CMKLR1 CON - CMKLR1 SIM	-.44333	.10693	.06173	-.70895	-.17771	.019
Pair group 5	GPR1 CON - GPR1 SIM	-.12667	.08737	.05044	-.34370	.09037	.129

PPAR γ , peroxisome proliferator-activated receptor γ ; CMKLR1, chemokine-like receptor 1; GPR1, G protein-coupled receptor 1; CON, control; SIM, simvastatin.

Table SV. Analysis by Student's t-test of the data of the paired samples of the 14-day group presented in Figs. 2, S1 and S2A.

	Difference						
	Average	Standard deviation	Average standard error	95% Confidence interval		Significance (two-tailed P-value)	
				Lower limit	Upper limit		
Pair group 1	.21667	.13204	.07623	-.11133	.54466	.105	
Pair group 2	.70667	.28148	.16251	.00742	1.40591	.049	
Pair group 3	.20333	.07572	.04372	.01524	.39143	.043	
Pair group 4	-1.26000	.19079	.11015	-1.73394	-.78606	.008	
Pair group 5	-1.37667	.21733	.12548	-1.91655	-.83678	.008	

PPAR γ , peroxisome proliferator-activated receptor γ ; CMKLR1, chemokine-like receptor 1; GPR1, G protein-coupled receptor 1; CON, control; SIM, simvastatin.

Table SVI. Analysis by ANOVA followed by the LSD post hoc test of data of the samples of the 3-day group presented in Figs. 3 and S2B.

Variable	(I) Group	(J) Group	Average difference (I-J)	Standard error	Significance (P-value)	
CMKLR1	BLANK	NC	-.02000	.04123	.636	
		CKD	.52000 ^a	.04123	<.001	
		SIM+BLANK	.01667	.04123	.693	
		SIM+NC	.00667	.04123	.874	
		SIM+CKD	.49000 ^a	.04123	<.001	
	NC	BLANK	.02000	.04123	.636	
		CKD	.54000 ^a	.04123	<.001	
		SIM+BLANK	.03667	.04123	.391	
		SIM+NC	.02667	.04123	.530	
		SIM+CKD	.51000 ^a	.04123	<.001	
	CKD	BLANK	-.52000 ^a	.04123	<.001	
		NC	-.54000 ^a	.04123	<.001	
		SIM+BLANK	-.50333 ^a	.04123	<.001	
		SIM+NC	-.51333 ^a	.04123	<.001	
		SIM+CKD	-.03000	.04123	.481	
	SIM+BLANK	BLANK	-.01667	.04123	.693	
		NC	-.03667	.04123	.391	
		CKD	.50333 ^a	.04123	<.001	
		SIM+NC	-.01000	.04123	.812	
		SIM+CKD	.47333 ^a	.04123	<.001	
	SIM+NC	BLANK	-.00667	.04123	.874	
		NC	-.02667	.04123	.530	
		CKD	.51333 ^a	.04123	<.001	
		SIM+BLANK	.01000	.04123	.812	
		SIM+CKD	.48333 ^a	.04123	<.001	
	SIM+CKD	BLANK	-.49000 ^a	.04123	<.001	
		NC	-.51000 ^a	.04123	<.001	
		CKD	.03000	.04123	.481	
		SIM+BLANK	-.47333 ^a	.04123	<.001	
		SIM+NC	-.48333 ^a	.04123	<.001	
	GPR1	BLANK	NC	-.10333	.06046	.113
			CKD	.68667 ^a	.06046	<.001
			SIM+BLANK	-.07667	.06046	.229
			SIM+NC	-.11667	.06046	.078
			SIM+CKD	.67667 ^a	.06046	<.001
		NC	BLANK	.10333	.06046	.113
CKD			.79000 ^a	.06046	<.001	
SIM+BLANK			.02667	.06046	.667	
SIM+NC			-.01333	.06046	.829	
SIM+CKD			.78000 ^a	.06046	<.001	
CKD		BLANK	-.68667 ^a	.06046	<.001	
		NC	-.79000 ^a	.06046	<.001	
		SIM+BLANK	-.76333 ^a	.06046	<.001	
		SIM+NC	-.80333 ^a	.06046	<.001	
		SIM+CKD	-.01000	.06046	.871	
SIM+BLANK		BLANK	.07667	.06046	.229	
		NC	-.02667	.06046	.667	
		CKD	.76333 ^a	.06046	<.001	
		SIM+NC	-.04000	.06046	.521	
		SIM+CKD	.75333 ^a	.06046	<.001	
SIM+NC		BLANK	.11667	.06046	.078	
		NC	.01333	.06046	.829	
		CKD	.80333 ^a	.06046	<.001	
		SIM+BLANK	.04000	.06046	.521	
		SIM+CKD	.79333 ^a	.06046	<.001	

Table SVI. Continued.

Variable	(I) Group	(J) Group	Average difference (I-J)	Standard error	Significance (P-value)	
Adiponectin	SIM+CKD	BLANK	-.67667 ^a	.06046	<.001	
		NC	-.78000 ^a	.06046	<.001	
		CKD	.01000	.06046	.871	
		SIM+BLANK	-.75333 ^a	.06046	<.001	
		SIM+NC	-.79333 ^a	.06046	<.001	
	BLANK	NC	NC	-.22333	.33318	.515
			CKD	2.64333 ^a	.33318	<.001
			SIM+BLANK	.14000	.33318	.682
			SIM+NC	.07000	.33318	.837
			SIM+CKD	2.67333 ^a	.33318	<.001
		CKD	BLANK	.22333	.33318	.515
			CKD	2.86667 ^a	.33318	<.001
			SIM+BLANK	.36333	.33318	.297
			SIM+NC	.29333	.33318	.396
			SIM+CKD	2.89667 ^a	.33318	<.001
	CKD	BLANK	BLANK	-2.64333 ^a	.33318	<.001
			NC	-2.86667 ^a	.33318	<.001
			SIM+BLANK	-2.50333 ^a	.33318	<.001
			SIM+NC	-2.57333 ^a	.33318	<.001
			SIM+CKD	.03000	.33318	.930
		SIM+BLANK	BLANK	-.14000	.33318	.682
			NC	-.36333	.33318	.297
			CKD	2.50333 ^a	.33318	<.001
			SIM+NC	-.07000	.33318	.837
			SIM+CKD	2.53333 ^a	.33318	<.001
	SIM+NC	BLANK	BLANK	-.07000	.33318	.837
			NC	-.29333	.33318	.396
			CKD	2.57333 ^a	.33318	<.001
			SIM+BLANK	.07000	.33318	.837
			SIM+CKD	2.60333 ^a	.33318	<.001
SIM+CKD		BLANK	-2.67333 ^a	.33318	<.001	
		NC	-2.89667 ^a	.33318	<.001	
		CKD	-.03000	.33318	.930	
		SIM+BLANK	-2.53333 ^a	.33318	<.001	
		SIM+NC	-2.60333 ^a	.33318	<.001	

CMKLR1, chemokine-like receptor 1; GPR1, G protein-coupled receptor 1; BLANK, untransfected cells; NC, negative control; CKD, CMKLR1 knockdown; SIM, simvastatin. ^aThe average difference was significant at the 0.05 level.

Table SVII. Analysis by ANOVA followed by the LSD post hoc test of data of the samples of the 14-day group presented in Figs. 3 and S2B.

Variable	(I) Group	(J) Group	Average difference (I-J)	Standard error	Significance (P-value)
CMKLR1	BLANK	NC	.01000	.03844	.799
		CKD	.18000 ^a	.03844	.001
		SIM+BLANK	-.13333 ^a	.03844	.005
		SIM+NC	-.10000 ^a	.03844	.023
		SIM+CKD	.17000 ^a	.03844	.001
	NC	BLANK	-.01000	.03844	.799
		CKD	.17000 ^a	.03844	.001
		SIM+BLANK	-.14333 ^a	.03844	.003
		SIM+NC	-.11000 ^a	.03844	.014
		SIM+CKD	.16000 ^a	.03844	.001
	CKD	BLANK	-.18000 ^a	.03844	.001
		NC	-.17000 ^a	.03844	.001
		SIM+BLANK	-.31333 ^a	.03844	<.001
		SIM+NC	-.28000 ^a	.03844	<.001
		SIM+CKD	-.01000	.03844	.799
	SIM+BLANK	BLANK	.13333 ^a	.03844	.005
		NC	.14333 ^a	.03844	.003
		CKD	.31333 ^a	.03844	<.001
		SIM+NC	.03333	.03844	.403
		SIM+CKD	.30333 ^a	.03844	<.001
	SIM+NC	BLANK	.10000 ^a	.03844	.023
		NC	.11000 ^a	.03844	.014
		CKD	.28000 ^a	.03844	<.001
		SIM+BLANK	-.03333	.03844	.403
		SIM+CKD	.27000 ^a	.03844	<.001
	SIM+CKD	BLANK	-.17000 ^a	.03844	.001
		NC	-.16000 ^a	.03844	.001
		CKD	.01000	.03844	.799
		SIM+BLANK	-.30333 ^a	.03844	<.001
		SIM+NC	-.27000 ^a	.03844	<.001
GPR1	BLANK	NC	-.02667	.06719	.698
		CKD	.18667 ^a	.06719	.017
		SIM+BLANK	-.16000 ^a	.06719	.035
		SIM+NC	-.17333 ^a	.06719	.024
		SIM+CKD	.12333	.06719	.091
	NC	BLANK	.02667	.06719	.698
		CKD	.21333 ^a	.06719	.008
		SIM+BLANK	-.13333	.06719	.071
		SIM+NC	-.14667 ^a	.06719	.050
		SIM+CKD	.15000 ^a	.06719	.045
	CKD	BLANK	-.18667 ^a	.06719	.017
		NC	-.21333 ^a	.06719	.008
		SIM+BLANK	-.34667 ^a	.06719	<.001
		SIM+NC	-.36000 ^a	.06719	<.001
		SIM+CKD	-.06333	.06719	.364
	SIM+BLANK	BLANK	.16000 ^a	.06719	.035
		NC	.13333	.06719	.071
		CKD	.34667 ^a	.06719	<.001
		SIM+NC	-.01333	.06719	.846
		SIM+CKD	.28333 ^a	.06719	.001
	SIM+NC	BLANK	.17333 ^a	.06719	.024
		NC	.14667 ^a	.06719	.050
		CKD	.36000 ^a	.06719	<.001
		SIM+BLANK	.01333	.06719	.846
		SIM+CKD	.29667 ^a	.06719	.001

Table SVII. Continued.

Variable	(I) Group	(J) Group	Average difference (I-J)	Standard error	Significance (P-value)	
Adiponectin	SIM+CKD	BLANK	-.12333	.06719	.091	
		NC	-.15000 ^a	.06719	.045	
		CKD	.06333	.06719	.364	
		SIM+BLANK	-.28333 ^a	.06719	.001	
		SIM+NC	-.29667 ^a	.06719	.001	
	BLANK	NC	NC	-4.94333	7.93636	.545
			CKD	86.80333 ^a	7.93636	<.001
			SIM+BLANK	59.55333 ^a	7.93636	<.001
			SIM+NC	54.72667 ^a	7.93636	<.001
			SIM+CKD	89.49667 ^a	7.93636	<.001
		CKD	BLANK	4.94333	7.93636	.545
			CKD	91.74667 ^a	7.93636	<.001
			SIM+BLANK	64.49667 ^a	7.93636	<.001
			SIM+NC	59.67000 ^a	7.93636	<.001
			SIM+CKD	94.44000 ^a	7.93636	<.001
	CKD	BLANK	BLANK	-86.80333 ^a	7.93636	<.001
			NC	-91.74667 ^a	7.93636	<.001
			SIM+BLANK	-27.25000 ^a	7.93636	.005
			SIM+NC	-32.07667 ^a	7.93636	.002
			SIM+CKD	2.69333	7.93636	.740
	SIM+BLANK	BLANK	BLANK	-59.55333 ^a	7.93636	<.001
			NC	-64.49667 ^a	7.93636	<.001
			CKD	27.25000 ^a	7.93636	.005
			SIM+NC	-4.82667	7.93636	.554
			SIM+CKD	29.94333 ^a	7.93636	.003
	SIM+NC	BLANK	BLANK	-54.72667 ^a	7.93636	<.001
			NC	-59.67000 ^a	7.93636	<.001
			CKD	32.07667 ^a	7.93636	.002
			SIM+BLANK	4.82667	7.93636	.554
			SIM+CKD	34.77000 ^a	7.93636	.001
SIM+CKD	BLANK	BLANK	-89.49667 ^a	7.93636	<.001	
		NC	-94.44000 ^a	7.93636	<.001	
		CKD	-2.69333	7.93636	.740	
		SIM+BLANK	-29.94333 ^a	7.93636	.003	
		SIM+NC	-34.77000 ^a	7.93636	.001	

CMKLR1, chemokine-like receptor 1; GPR1, G protein-coupled receptor 1; BLANK, untransfected cells; NC, negative control; CKD, CMKLR1 knockdown; SIM, simvastatin. ^aThe average difference was significant at the 0.05 level.

Table SVIII. Analysis by ANOVA followed by the LSD post hoc test of data of the samples of Oil Red O staining presented in Fig. 3.

(I) Group	(J) Group	Average difference (I-J)	Standard error	Significance (P-value)	95% Confidence interval	
					Lower limit	Upper limit
CON (BLANK)	CON (NC)	.07667	.05121	.160	-.0349	.1882
	CON (CKD)	.63000 ^a	.05121	<.001	.5184	.7416
	SIM (BLANK)	.35667 ^a	.05121	<.001	.2451	.4682
	SIM (NC)	.42000 ^a	.05121	<.001	.3084	.5316
	SIM (CKD)	.63667 ^a	.05121	<.001	.5251	.7482
CON (NC)	CON (BLANK)	-.07667	.05121	.160	-.1882	.0349
	CON (CKD)	.55333 ^a	.05121	<.001	.4418	.6649
	SIM (BLANK)	.28000 ^a	.05121	<.001	.1684	.3916
	SIM (NC)	.34333 ^a	.05121	<.001	.2318	.4549
	SIM (CKD)	.56000 ^a	.05121	<.001	.4484	.6716
CON (CKD)	CON (BLANK)	-.63000 ^a	.05121	<.001	-.7416	-.5184
	CON (NC)	-.55333 ^a	.05121	<.001	-.6649	-.4418
	SIM (BLANK)	-.27333 ^a	.05121	<.001	-.3849	-.1618
	SIM (NC)	-.21000 ^a	.05121	.001	-.3216	-.0984
	SIM (CKD)	.00667	.05121	.899	-.1049	.1182
SIM (BLANK)	CON (BLANK)	-.35667 ^a	.05121	<.001	-.4682	-.2451
	CON (NC)	-.28000 ^a	.05121	<.001	-.3916	-.1684
	CON (CKD)	.27333 ^a	.05121	<.001	.1618	.3849
	SIM (NC)	.06333	.05121	.240	-.0482	.1749
	SIM (CKD)	.28000 ^a	.05121	<.001	.1684	.3916
SIM (NC)	CON (BLANK)	-.42000 ^a	.05121	<.001	-.5316	-.3084
	CON (NC)	-.34333 ^a	.05121	<.001	-.4549	-.2318
	CON (CKD)	.21000 ^a	.05121	.001	.0984	.3216
	SIM (BLANK)	-.06333	.05121	.240	-.1749	.0482
	SIM (CKD)	.21667 ^a	.05121	.001	.1051	.3282
SIM (CKD)	CON (BLANK)	-.63667 ^a	.05121	<.001	-.7482	-.5251
	CON (NC)	-.56000 ^a	.05121	<.001	-.6716	-.4484
	CON (CKD)	-.00667	.05121	.899	-.1182	.1049
	SIM (BLANK)	-.28000 ^a	.05121	<.001	-.3916	-.1684
	SIM (NC)	-.21667 ^a	.05121	.001	-.3282	-.1051

ANOVA, analysis of variance; CON, control; SIM, simvastatin; BLANK, untransfected cells; NC, negative control; CKD, CMKLR1 knock-down. ^aThe average difference was significant at the 0.05 level.

Table SIX. Analysis by ANOVA followed by the LSD post hoc test of the data of the samples of the 3-day group presented in Figs. 4 and S2C.

Variable	(I) Group	(J) Group	Average difference (I-J)	Standard error	Significance (P-value)
PPAR γ	CON	ROSI	-56.80667 ^a	4.42400	<.001
		ROSI+SIM	-42.52000 ^a	4.42400	<.001
		SIM	1.50667	4.42400	.742
	ROSI	CON	56.80667 ^a	4.42400	<.001
		ROSI+SIM	14.28667 ^a	4.42400	.012
		SIM	58.31333 ^a	4.42400	<.001
	ROSI+SIM	CON	42.52000 ^a	4.42400	<.001
		ROSI	-14.28667 ^a	4.42400	.012
		SIM	44.02667 ^a	4.42400	<.001
	SIM	CON	-1.50667	4.42400	.742
		ROSI	-58.31333 ^a	4.42400	<.001
		ROSI+SIM	-44.02667 ^a	4.42400	<.001
Adiponectin	CON	ROSI	-.28000	.58045	.642
		ROSI+SIM	.10333	.58045	.863
		SIM	.21000	.58045	.727
	ROSI	CON	.28000	.58045	.642
		ROSI+SIM	.38333	.58045	.528
		SIM	.49000	.58045	.423
	ROSI+SIM	CON	-.10333	.58045	.863
		ROSI	-.38333	.58045	.528
		SIM	.10667	.58045	.859
	SIM	CON	-.21000	.58045	.727
		ROSI	-.49000	.58045	.423
		ROSI+SIM	-.10667	.58045	.859
Chemerin	CON	ROSI	-11.67333 ^a	1.02764	<.001
		ROSI+SIM	-8.72000 ^a	1.02764	<.001
		SIM	-.30333	1.02764	.775
	ROSI	CON	11.67333 ^a	1.02764	<.001
		ROSI+SIM	2.95333 ^a	1.02764	.021
		SIM	11.37000 ^a	1.02764	<.001
	ROSI+SIM	CON	8.72000 ^a	1.02764	<.001
		ROSI	-2.95333 ^a	1.02764	.021
		SIM	8.41667 ^a	1.02764	<.001
	SIM	CON	.30333	1.02764	.775
		ROSI	-11.37000 ^a	1.02764	<.001
		ROSI+SIM	-8.41667 ^a	1.02764	<.001
CMKLR1	CON	ROSI	.26333 ^a	.06888	.005
		ROSI+SIM	.19000 ^a	.06888	.025
		SIM	-.01667	.06888	.815
	ROSI	CON	-.26333 ^a	.06888	.005
		ROSI+SIM	-.07333	.06888	.318
		SIM	-.28000 ^a	.06888	.004
	ROSI+SIM	CON	-.19000 ^a	.06888	.025
		ROSI	.07333	.06888	.318
		SIM	-.20667 ^a	.06888	.017
	SIM	CON	.01667	.06888	.815
		ROSI	.28000 ^a	.06888	.004
		ROSI+SIM	.20667 ^a	.06888	.017
GPR1	CON	ROSI	.23000 ^a	.08528	.027
		ROSI+SIM	.20333 ^a	.08528	.044
		SIM	.08333	.08528	.357
	ROSI	CON	-.23000 ^a	.08528	.027
		ROSI+SIM	-.02667	.08528	.763
		SIM	-.14667	.08528	.124
	ROSI+SIM	CON	-.20333 ^a	.08528	.044
		ROSI	.02667	.08528	.763
		SIM	-.12000	.08528	.197

Table SIX. Continued.

Variable	(I) Group	(J) Group	Average difference (I-J)	Standard error	Significance (P-value)
	SIM	CON	-.08333	.08528	.357
		ROSI	.14667	.08528	.124
		ROSI+SIM	.12000	.08528	.197

ANOVA, analysis of variance; PPAR γ , peroxisome proliferator-activated receptor γ ; CMKLR1, chemokine-like receptor 1; GPR1, G protein-coupled receptor 1; CON, control; ROSI, rosiglitazone; SIM, simvastatin. ^aThe average difference was significant at the 0.05 level.

Table SX. Analysis by ANOVA followed by the LSD post hoc test of the data of the samples of the 14-day group presented in Figs. 4 and S2C.

Variable	(I) Group	(J) Group	Average difference (I-J)	Standard error	Significance (P-value)
PPAR γ	CON	ROSI	-56.37667 ^a	8.73120	<.001
		ROSI+SIM	-25.32333 ^a	8.73120	.020
		SIM	21.28667 ^a	8.73120	.041
	ROSI	CON	56.37667 ^a	8.73120	<.001
		ROSI+SIM	31.05333 ^a	8.73120	.007
		SIM	77.66333 ^a	8.73120	<.001
	ROSI+SIM	CON	25.32333 ^a	8.73120	.020
		ROSI	-31.05333 ^a	8.73120	.007
		SIM	46.61000 ^a	8.73120	.001
	SIM	CON	-21.28667 ^a	8.73120	.041
		ROSI	-77.66333 ^a	8.73120	<.001
		ROSI+SIM	-46.61000 ^a	8.73120	.001
Adiponectin	CON	ROSI	-35.33333 ^a	9.35407	.005
		ROSI+SIM	29.66333 ^a	9.35407	.013
		SIM	53.15000 ^a	9.35407	<.001
	ROSI	CON	35.33333 ^a	9.35407	.005
		ROSI+SIM	64.99667 ^a	9.35407	<.001
		SIM	88.48333 ^a	9.35407	<.001
	ROSI+SIM	CON	-29.66333 ^a	9.35407	.013
		ROSI	-64.99667 ^a	9.35407	<.001
		SIM	23.48667 ^a	9.35407	.036
	SIM	CON	-53.15000 ^a	9.35407	<.001
		ROSI	-88.48333 ^a	9.35407	<.001
		ROSI+SIM	-23.48667 ^a	9.35407	.036
Chemerin	CON	ROSI	-37.71000 ^a	12.27690	.015
		ROSI+SIM	2.52667	12.27690	.842
		SIM	32.39667 ^a	12.27690	.030
	ROSI	CON	37.71000 ^a	12.27690	.015
		ROSI+SIM	40.23667 ^a	12.27690	.011
		SIM	70.10667 ^a	12.27690	<.001
	ROSI+SIM	CON	-2.52667	12.27690	.842
		ROSI	-40.23667 ^a	12.27690	.011
		SIM	29.87000 ^a	12.27690	.041
	SIM	CON	-32.39667 ^a	12.27690	.030
		ROSI	-70.10667 ^a	12.27690	<.001
		ROSI+SIM	-29.87000 ^a	12.27690	.041
CMKLR1	CON	ROSI	.16000 ^a	.05935	.027
		ROSI+SIM	-.01000	.05935	.870
		SIM	-.28000 ^a	.05935	.002
	ROSI	CON	-.16000 ^a	.05935	.027
		ROSI+SIM	-.17000 ^a	.05935	.021
		SIM	-.44000 ^a	.05935	<.001
	ROSI+SIM	CON	.01000	.05935	.870
		ROSI	.17000 ^a	.05935	.021
		SIM	-.27000 ^a	.05935	.002
	SIM	CON	.28000 ^a	.05935	.002
		ROSI	.44000 ^a	.05935	<.001
		ROSI+SIM	.27000 ^a	.05935	.002
GPR1	CON	ROSI	.22333 ^a	.08759	.034
		ROSI+SIM	.09333	.08759	.318
		SIM	-.20667 ^a	.08759	.046
	ROSI	CON	-.22333 ^a	.08759	.034
		ROSI+SIM	-.13000	.08759	.176
		SIM	-.43000 ^a	.08759	.001
	ROSI+SIM	CON	-.09333	.08759	.318
		ROSI	.13000	.08759	.176
		SIM	-.30000 ^a	.08759	.009

Table SX. Continued.

Variable	(I) Group	(J) Group	Average difference (I-J)	Standard error	Significance (P-value)
	SIM	CON	.20667 ^a	.08759	.046
		ROSI	.43000 ^a	.08759	.001
		ROSI+SIM	.30000 ^a	.08759	.009

ANOVA, analysis of variance; PPAR γ , peroxisome proliferator-activated receptor γ ; CMKLR1, chemokine-like receptor 1; GPR1, G protein-coupled receptor 1; CON, control; ROSI, rosiglitazone; SIM, simvastatin. ^aThe average difference was significant at the 0.05 level.